Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics characterization of astrocyte subtypes reveals spatially coordinated astrocyte downregulation in depression.

bioRxiv : the preprint server for biology·2026
Same author

Correction: A genome-wide investigation of depression among individuals with and without irritability.

Molecular psychiatry·2026
Same author

Dopamine drives persistent remodelling of the maternal brain.

Nature·2026
Same author

Cognitive effects of intravenous Ketamine in treatment-resistant depression: A systematic review.

Psychological medicine·2026
Same author

Astrocyte fatty acid metabolism as a driver of risk for major depressive disorder.

Nature communications·2026
Same author

Characterization of the chromosome 7 locus associated with suicidal behavior.

Molecular psychiatry·2026

Related Experiment Video

Updated: Jun 24, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Antidepressant-Induced Sexual Dysfunction in Adults: A Targeted Scoping Review and Clinical Update.

Jonathan Zini1, Gustavo Turecki1,2

  • 1McGill University.

Journal of Clinical Psychopharmacology
|June 23, 2026
PubMed
Summary

Antidepressant-induced sexual dysfunction (AISD) is common, especially with SSRIs/SNRIs. Management involves dose changes, switching medications, or adjunctive therapies, but optimal strategies require more research.

Keywords:
PSSDSNRIsSSRIsanorgasmiaantidepressant-induced sexual dysfunctionbupropionlibido losspsychopharmacologysexual side effectstreatment adherence

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Medicine

Background:

  • Antidepressant-induced sexual dysfunction (AISD) is a frequent adverse effect impacting patient quality of life and treatment adherence.
  • Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly associated with AISD.

Purpose of the Study:

  • To review the prevalence, risk factors, neurobiological mechanisms, and clinical management of AISD in adults.
  • To examine emerging evidence on post-SSRI sexual dysfunction (PSSD) and potential mitigation strategies.

Main Methods:

  • A targeted scoping review with narrative synthesis was performed.
  • PubMed was searched for English-language studies published between 2000 and 2025, with 65 studies included.

Main Results:

  • AISD is common, with risk factors including higher antidepressant dose, male sex, older age, pre-existing sexual dysfunction, and depressive severity.
  • Proposed mechanisms involve serotonergic, dopaminergic, and nitric oxide pathways, with potential epigenetic factors in PSSD.
  • Bupropion, mirtazapine, and agomelatine show favorable sexual side effect profiles; management includes dose reduction, switching agents, or augmentation with PDE5 inhibitors or bupropion.

Conclusions:

  • AISD is multifactorial, potentially persistent, and impacts adherence and quality of life.
  • Individualized assessment and intervention are crucial, though optimal strategies are not fully defined.
  • Further research into PSSD pathophysiology, prevalence, and treatment is needed.